Trial
NCT02599129
A Study of Secukinumab for the Treatment of Alopecia Areata
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Novartis
Condition
Alopecia Areata
Intervention
Secukinumab
Why stopped
low enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-11